Advances in Chronic Kidney Disease
Volume 14, Issue 2 , Pages 191-198 , April 2007

Medications During Pregnancy: Antihypertensives and Immunosuppressives

  • Jason G. Umans

      Affiliations

    • Penn Medical Laboratory, MedStar Research Institute, Washington, DC
    • Department of Medicine, Georgetown University, Washington, DC
    • Department of Obstetrics and Gynecology, Georgetown University, Washington, DC.
    • Corresponding Author InformationAddress correspondence to Jason G. Umans, MD, PhD, 108 Irving Street, NW - Annex 2, Washington, DC 20010-2975.

References 

  1. Bonati M, Bortolus R, Marchetti F, et al. Drug use in pregnancy: An overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol. 1990;38:325–328
  2. Glover DD, Amonkar M, Rybeck BF, et al. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol. 2003;188:1039–1045
  3. Mitchell AA, Hernández-Díaz S, Louik C, et al. Medication use in pregnancy. Pharmacoepidemiol Drug Saf. 2001;10(suppl):S146
  4. De Vigan C, De Walle HE, Cordier S, et al. Therapeutic drug use during pregnancy: A comparison in four European countries (OECM Working Group. Occupational Exposures and Congenital Anomalies). J Clin Epidemiol. 1999;52:977–982
  5. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet. 2000;356:1735–1736
  6. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: Are they a reliable source of information?. Drug Saf. 2000;23:245–253
  7. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol. 2004;18:106–111
  8. Friedman JM, Polifka JE. Teratogenic Effects of Drugs: A Resource for Clinicians (TERIS). Baltimore, MD: Johns Hopkins University Press; 2000;
  9. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy: a Reference Guide to Fetal and Neonatal Risk. (ed 7). Philadelphia, PA: Lippincott Williams & Wilkins; 2005;
  10. http://motherisk.org/prof/index.jsp
  11. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633–639
  12. Hogstedt S, Lindberg B, Peng DR, et al. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther. 1985;37:688–692
  13. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62:400–407
  14. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73:330–337
  15. Ferguson JE, Schutz T, Pershe R, et al. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol. 1989;161:1485–1490
  16. Barton JR, Prevost RR, Wilson DA, et al. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am J Obstet Gynecol. 1991;165:951–954
  17. Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003;17:1195–1199
  18. Brazier JL, Ritter J, Berland M, et al. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther. 1983;6:315–322
  19. Caritis SN, Lin LS, Wong LK. Evaluation of the pharmacodynamics and pharmacokinetics of ritodrine when administered as a loading dose: On establishing a potentially useful drug administration regimen in cases of fetal distress. Am J Obstet Gynecol. 1985;152:1026–1031
  20. Garland M, Szeto HH, Daniel SS, et al. Zidovudine kinetics in the pregnant baboon. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:117–127
  21. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reprod Toxicol. 2006;22:400–410
  22. Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol. 2005;289:R963–R969
  23. Josephson MA, McKay DB. Considerations in the medical management of pregnancy in transplant recipients. Adv Chronic Kid Dis. 2007;14:156–167
  24. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127:264–267
  25. Saarikoski S, Seppala M. Immunosuppression during pregnancy: Transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115:1100–1106
  26. Armenti VT, Moritz MJ, Radomski JS, et al. Pregnancy and transplantation. Graft. 2000;3:59–63
  27. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222–239
  28. Jain AB, Shapiro R, Scantlebury VP, et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: A single center’s experience. Transplantation. 2004;77:897–902
  29. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: Report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005;5:1592–1599
  30. Soldin SJ, Steele BW, Witte DL, et al. Lack of specificity of cyclosporine immunoassays: Results of a College of American Pathologists Study. Arch Pathol Lab Med. 2003;127:19–22
  31. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet. 2000;355:712–715
  32. Podymow T, August P. Hypertension in pregnancy. Adv Chronic Kid Dis. 2007;14:178–190
  33. Report of the National High Blood Pressure Education Project Working Group on High Blood Pressure in Pregnancy, NIH Publication No. 00-3029, July 2000, 38 pp. Available at: URL: http://www.nhlbi.nih.gov/health/prof/heart/hbp_preg.htm
  34. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: Full consensus statement. Aust N Z J Obstet Gynecol. 2000;40:139–155
  35. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Hypertension Society consensus conference: 3 (Pharmacologic treatment of hypertensive disorders in pregnancy). Can Med Assoc J. 1997;157:1245–1254
  36. Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: A review. Obstet Gynecol. 2000;96:849–860
  37. Magee LA, Duley L. Oral beta blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;3:CD002863
  38. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2001;2:CD002252
  39. Duley L, Henderson-Smart DJ. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006;3:CD001449
  40. Hebert MF, Carr DB, Anderson GD, et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol. 2005;45:25–33
  41. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: The effects of specific treatment on the growth and development of the children. Lancet. 1982;1:647–649
  42. Ray JG, Vermeulen MJ, Burrows EA, et al. Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster outcome study of hypertension in pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth. 2001;1:6
  43. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587–589
  44. Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birthweight. Am J Cardiol. 1997;79:1436–1438
  45. Bayliss H, Churchill D, Beevers M, et al. Anti-hypertensive drugs in pregnancy and fetal growth: Evidence for “pharmacological programming” in the first trimester?. Hypertens Pregnancy. 2002;21:161–174
  46. Easterling TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia: A randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol. 1999;93:725–733
  47. Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. BMJ. 1985;290:17–23
  48. Serreau R, Luton D, Macher MA, et al. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: A report of 10 cases. BJOG. 2005;112:710–712
  49. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol. 1995;9:382–385
  50. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep. 1997;46:240–242
  51. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–2451
  52. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis. BMJ. 2003;327:955–960
  53. Vigil-De Gracia P, Lasso M, Ruiz E, et al. Severe hypertension in pregnancy: Hydralazine or labetalol A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128:157–162
  54. Hanff LM, Vulto AG, Bartels PA, et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients. J Hypertens. 2005;23:2319–2326
  55. Easterling TR, Carr DB, Davis C, et al. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol. 2000;96:956–961

 Supported in part by grants from NICHD (5U10HD047890) and NCRR (1M01RR020359).

PII: S1548-5595(07)00010-9

doi: 10.1053/j.ackd.2007.01.009

Advances in Chronic Kidney Disease
Volume 14, Issue 2 , Pages 191-198 , April 2007

Article Tools